Hoskin P J Motohashi K

[3] Hoskin, P. J., Motohashi, K., Bownes, P., Bryant, L., & Ostler, P. (2007). High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol 84(2), 114–120.
[5] NCCN clinical practice guidelines in oncology. Prostate cancer version 4. 2013. Available at: http://nccn.org.
[7] Initial REport of NRG oncology/RTOG 0232: A phase III study comparing combined external beam TRIzol and transperineal intersti-
tial permanent brachytherapy with brachytherapy alone for selected pa-tients with intermediate risk prostatic carcinoma identification and validation of intrinsic subtypes of prostate cancer (2016). In K. Prestidge BRW, M. G. Sanda, & M. Amin, et al. (Eds.). Int J Radiat Oncol Biol Phys 96(Suppl 4), 4, ASTRO, Boston, MA.
[10] Rodda, S., Tyldesley, S., & Morris, W. J., et al. (2017). ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 98(2), 286–295.
[14] Lawton, C. A., DeSilvio, M., & Lee, W. R., et al. (2007). Results of a phase II trial of transrectal ultrasound-guided permanent radioactive im-plantation of the prostate for definitive management of localized adeno-carcinoma of the prostate (radiation therapy oncology group 98-05). Int J Radiat Oncol Biol Phys 67(1), 39–47.
Contents lists available at ScienceDirect
Hepatobiliary & Pancreatic Diseases International
journal homepage: www.elsevier.com/locate/hbpd
Original Article/Pancreas
Combined preoperative platelet-to-lymphocyte ratio and serum carbohydrate antigen 19–9 level as a prognostic factor in patients with resected pancreatic cancer
Teruhisa Sakamoto, Hiroaki Saito∗, Masataka Amisaki, Naruo Tokuyasu, Soichiro Honjo, Yoshiyuki Fujiwara
Division of Surgical Oncology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine, 36-1 Nishi-cho, Yonago 683-8504, Japan
Article history:
Keywords:
Pancreatic cancer Platelet-to-lymphocyte ratio Prognosis 
Background: Carbohydrate antigen 19–9 (CA19-9) is the most frequently used tumor marker and serves as a prognostic indicator in patients with pancreatic cancer (PC). The platelet-to-lymphocyte ratio (PLR) is thought to be an inflammation-related serum marker. An elevated PLR represents increased inflammatory status and is associated with poor prognosis in patients with various cancers including PC.
Methods: This study involved 103 patients with a histopathological diagnosis of pancreatic ductal ade-nocarcinoma who underwent pancreatectomy. The patients were assessed to determine the prognostic significance of the combination of the PLR and CA19-9 level.
and 16.8%, respectively (P = 0.002). Multivariate analysis revealed that the combination of the PLR and CA19-9 was an independent prognostic factor in patients with resected PC.
Conclusions: The combination of the PLR and CA19-9 is useful for predicting the prognosis of patients with resected PC.
© 2019 First A liated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.
Introduction
Pancreatectomy with regional lymph node dissection is the mainstay curative treatment for pancreatic cancer (PC). However, the survival of patients with PC after macroscopically curative re-section remains low (5-year survival rate of 20.7%−23.9%, median survival duration of 22.3–23.6 months) even after administration of adjuvant chemotherapy using gemcitabine [1–3]. A recent study showed that the 5-year overall survival (OS) rate of patients with stage I to III PC with no local residual or microscopic residual tu-mor after pancreatectomy with regional lymph node dissection im-proved up to 44.1% by using S-1 as adjuvant chemotherapy [4]. Thus, identifying and carefully monitoring patients with PC with a